Erlotinib hydrochloride

    WARNING: This product is for research use only, not for human or veterinary use.

MedKoo CAT#: 100300

CAS#: 183319-69-9 (HCl)

Description: Erlotinib hydrochloride is the hydrochloride salt of a quinazoline derivative with antineoplastic properties. Competing with adenosine triphosphate, erlotinib reversibly binds to the intracellular catalytic domain of epidermal growth factor receptor (EGFR) tyrosine kinase, thereby reversibly inhibiting EGFR phosphorylation and blocking the signal transduction events and tumorigenic effects associated with EGFR activation.

Price and Availability


USD 150
USD 650
USD 2950

USD 250
USD 1050
USD 3950

USD 450
USD 1750
USD 5950

Erlotinib hydrochloride, purity > 98%, is in stock. The same day shipping out after order is received. Note: the estimated shipping out time for order > 200g may be 2 weeks.

Chemical Structure


Theoretical Analysis

MedKoo Cat#: 100300
Name: Erlotinib hydrochloride
CAS#: 183319-69-9 (HCl)
Chemical Formula: C22H24ClN3O4
Exact Mass:
Molecular Weight: 429.9
Elemental Analysis: C, 61.47; H, 5.63; Cl, 8.25; N, 9.77; O, 14.89

Related CAS #: 183319-69-9 (HCl)   183321-74-6 (free base)    

Synonym: CP-358,774; CP-358774; CP358774; OSI-774; OSI 774; OSI774; Erlotinib hydrochloride; US brand name: Tarceva.

IUPAC/Chemical Name: N-(3-Ethynylphenyl)-6,7-bis(2-methoxyethoxy)-4-quinazolinamine Monohydrochloride.


InChi Code: InChI=1S/C22H23N3O4.ClH/c1-4-16-6-5-7-17(12-16)25-22-18-13-20(28-10-8-26-2)21(29-11-9-27-3)14-19(18)23-15-24-22;/h1,5-7,12-15H,8-11H2,2-3H3,(H,23,24,25);1H


Technical Data

White to off-white solid powder

>98% (or refer to the Certificate of Analysis)

Safety Data Sheet (MSDS):

Shipping Condition:
Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.

Storage Condition:
Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).

Soluble in DMSO at 18 mg/mL with warming; very poorly soluble in ethanol; very poorly soluble in water; maximum solubility in plain water is estimated to be about 5-20 µM.

Shelf Life:
>10 years if stored properly

Drug Formulation:
This drug may be formulated in DMSO

Stock Solution Storage:
0 - 4 C for short term (days to weeks), or -20 C for long term (months).

Harmonized System Code:


1: Ellis PM, Coakley N, Feld R, Kuruvilla S, Ung YC. Use of the epidermal growth factor receptor inhibitors gefitinib, erlotinib, afatinib, dacomitinib, and icotinib in the treatment of non-small-cell lung cancer: a systematic review. Curr Oncol. 2015 Jun;22(3):e183-215. doi: 10.3747/co.22.2566. Review. PubMed PMID: 26089730; PubMed Central PMCID: PMC4462541.

2: Landi L, Cappuzzo F. Experience with erlotinib in the treatment of non-small cell lung cancer. Ther Adv Respir Dis. 2015 Aug;9(4):146-63. doi: 10.1177/1753465815588053. Epub 2015 Jun 10. Review. PubMed PMID: 26063687.

3: Macerelli M, Mazzer M, Foltran L, Cardellino GG, Aprile G. Erlotinib-associated interstitial lung disease in advanced pancreatic carcinoma: a case report and literature review. Tumori. 2015 Jul 24;101(4):e122-7. doi: 10.5301/tj.5000327. Review. PubMed PMID: 25953445.

4: Kelley MJ, McCrory DC. The Relative Efficacy of Oral Cancer Therapy for Medicare Beneficiaries Versus Currently Covered Therapy: Part 1, Gefitinib and Erlotinib for Non-Small Cell Lung Cancer [Internet]. Rockville (MD): Agency for Healthcare Research and Quality (US); 2005 Nov 15. Available from PubMed PMID: 25927123.

5: Zhou JG, Tian X, Wang X, Tian JH, Wang Y, Wang F, Zhang Y, Ma H. Treatment on advanced NSCLC: platinum-based chemotherapy plus erlotinib or platinum-based chemotherapy alone? A systematic review and meta-analysis of randomised controlled trials. Med Oncol. 2015 Feb;32(2):471. doi: 10.1007/s12032-014-0471-0. Epub 2015 Jan 13. Review. PubMed PMID: 25579169.

6: Singh N, Jindal A, Behera D. Erlotinib usage after prior treatment with gefitinib in advanced non-small cell lung cancer: A clinical perspective and review of published literature. World J Clin Oncol. 2014 Dec 10;5(5):858-64. doi: 10.5306/wjco.v5.i5.858. Review. PubMed PMID: 25493223; PubMed Central PMCID: PMC4259947.

7: Celik T, Kosker M. Ocular side effects and trichomegaly of eyelashes induced by erlotinib: a case report and review of the literature. Cont Lens Anterior Eye. 2015 Feb;38(1):59-60. doi: 10.1016/j.clae.2014.08.005. Epub 2014 Sep 22. Review. PubMed PMID: 25249292.

8: Togashi Y, Hayashi H, Nakagawa K, Nishio K. Clinical utility of erlotinib for the treatment of non-small-cell lung cancer in Japanese patients: current evidence. Drug Des Devel Ther. 2014 Jul 31;8:1037-46. doi: 10.2147/DDDT.S50358. eCollection 2014. Review. PubMed PMID: 25114510; PubMed Central PMCID: PMC4124069.

9: Durand M, Logerot S, Fonrose X, Schir E. [Treatment with erlotinib after gefitinib induced hepatotoxicity: literature review and case report]. Therapie. 2014 Mar-Apr;69(2):163-8. doi: 10.2515/therapie/2014017. Epub 2014 Jun 12. Review. French. PubMed PMID: 24926635.

10: Addeo R, Zappavigna S, Parlato C, Caraglia M. Erlotinib: early clinical development in brain cancer. Expert Opin Investig Drugs. 2014 Jul;23(7):1027-37. doi: 10.1517/13543784.2014.918950. Epub 2014 May 16. Review. PubMed PMID: 24836441.

11: Petit-Jean E, Buclin T, Guidi M, Quoix E, Gourieux B, Decosterd LA, Gairard-Dory AC, Ubeaud-Séquier G, Widmer N. Erlotinib: another candidate for the therapeutic drug monitoring of targeted therapy of cancer? A pharmacokinetic and pharmacodynamic systematic review of literature. Ther Drug Monit. 2015 Feb;37(1):2-21. doi: 10.1097/FTD.0000000000000097. Review. PubMed PMID: 24831652.

12: Steins M, Thomas M, Geissler M. Erlotinib. Recent Results Cancer Res. 2014;201:109-23. doi: 10.1007/978-3-642-54490-3_6. Review. PubMed PMID: 24756788.

13: Li W, Zhou F, Zhou C. Role of erlotinib in the targeted treatment of non-small-cell lung cancer in Chinese patients. Onco Targets Ther. 2014 Feb 13;7:253-61. doi: 10.2147/OTT.S45096. eCollection 2014. Review. PubMed PMID: 24611018; PubMed Central PMCID: PMC3928465.

14: Shi L, Tang J, Tong L, Liu Z. Risk of interstitial lung disease with gefitinib and erlotinib in advanced non-small cell lung cancer: a systematic review and meta-analysis of clinical trials. Lung Cancer. 2014 Feb;83(2):231-9. doi: 10.1016/j.lungcan.2013.11.016. Epub 2013 Nov 27. Review. PubMed PMID: 24332320.

15: Sakhri L, Mennecier B, Quoix A. [Hemolytic anemia under erlotinib treatment]. Rev Pneumol Clin. 2013 Dec;69(6):345-50. doi: 10.1016/j.pneumo.2013.06.003. Epub 2013 Oct 31. Review. French. PubMed PMID: 24183296.

16: Köhler J, Schuler M. Afatinib, erlotinib and gefitinib in the first-line therapy of EGFR mutation-positive lung adenocarcinoma: a review. Onkologie. 2013;36(9):510-8. doi: 10.1159/000354627. Epub 2013 Aug 19. Review. PubMed PMID: 24051929.

17: Tartarone A, Lazzari C, Lerose R, Conteduca V, Improta G, Zupa A, Bulotta A, Aieta M, Gregorc V. Mechanisms of resistance to EGFR tyrosine kinase inhibitors gefitinib/erlotinib and to ALK inhibitor crizotinib. Lung Cancer. 2013 Sep;81(3):328-36. doi: 10.1016/j.lungcan.2013.05.020. Epub 2013 Jun 25. Review. PubMed PMID: 23809060.

18: Zhuang H, Wang J, Zhao L, Yuan Z, Wang P. The theoretical foundation and research progress for WBRT combined with erlotinib for the treatment of multiple brain metastases in patients with lung adenocarcinoma. Int J Cancer. 2013 Nov 15;133(10):2277-83. doi: 10.1002/ijc.28290. Epub 2013 Jun 21. Review. PubMed PMID: 23720067.

19: D'Arcangelo M, Cappuzzo F. Erlotinib in the first-line treatment of non-small-cell lung cancer. Expert Rev Anticancer Ther. 2013 May;13(5):523-33. doi: 10.1586/era.13.23. Review. PubMed PMID: 23617344.

20: Kiyohara Y, Yamazaki N, Kishi A. Erlotinib-related skin toxicities: treatment strategies in patients with metastatic non-small cell lung cancer. J Am Acad Dermatol. 2013 Sep;69(3):463-72. doi: 10.1016/j.jaad.2013.02.025. Epub 2013 Apr 17. Review. PubMed PMID: 23602600.